-
11/05/2014
PAION AG reports results for the first nine month 2014
-
10/27/2014
PAION founds USA based subsidiary and engages an experienced U.S. industry expert as CEO
-
10/14/2014
Invitation to conference call of PAION about the project status of Remimazolam
-
10/01/2014
Two scientific Remimazolam presentations are accepted for ASA and ACG meeting in October 2014
-
09/24/2014
PAION AG grants license to YichangHumanwell for M6G in China
-
08/27/2014
Abdelghani Omari appointed as new Chief Financial Officer at PAION AG
-
08/06/2014
PAION AG reports financial results for the first half year 2014
-
07/09/2014
PAION grants licence to Remimazolam in Canada to Pendopharm
-
06/18/2014
PAION AG starts capital increase with subscription rights through the issue of 18.5 million shares at EUR 2.50 per share
-
06/17/2014
PAION grants licence for “Mena Region" to R-Pharm
-
06/13/2014
PAION grants Pendopharm exclusive option to Remimazolam in Canada
-
05/28/2014
PAION reports positive Phase II results of its short acting anaesthetic Remimazolam in major cardiac surgery
-
05/21/2014
Annual general Meeting approved share capital increase and elected
-
05/07/2014
PAION AG reports results for the first quarter 2014
-
04/11/2014
PAION AG plans capital increase with subscription rights by issuing up to 18.5 million shares to fund the Remimazolam programmes required for approval in the US and EU
-
04/07/2014
Planned transition in Prime Standard completed
-
03/12/2014
PAION AG reports financial results for the full year 2013
-
02/11/2014
PAION completes Phase II study with Remimazolam in indication anaesthesia
-
01/16/2014
PAION AG plans to issue up to 2.5 million shares in a private placement
-
01/15/2014
PAION AG successfully completes capital increase with subscription rights